Cynata’s Stem Cell Therapy Aids Lung Repair

Cynata Therapeutics Limited (AU:CYP) has released an update.

Cynata Therapeutics Limited has announced results from a study showing their Cymerus™ MSC therapy can significantly reverse pulmonary fibrosis and lung stiffness, offering hope for a novel treatment option for this fatal lung disease. This therapy, derived from induced pluripotent stem cells, demonstrated potent anti-inflammatory effects and the restoration of lung compliance in a preclinical model. The study, which aligns with Cynata’s focus on regenerative medicine, was published in the journal Biomedicine & Pharmacotherapy.

For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.